Agenus Inc (NASDAQ:AGEN) traded up 6.3% during mid-day trading on Thursday . The company traded as high as $2.23 and last traded at $2.19. 1,546,321 shares traded hands during trading, an increase of 5% from the average session volume of 1,468,994 shares. The stock had previously closed at $2.06.
Separately, Zacks Investment Research upgraded shares of Agenus from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Tuesday, August 14th.
The stock has a market cap of $230.37 million, a PE ratio of -1.78 and a beta of 2.19.
Institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Agenus by 15.7% during the 2nd quarter. BlackRock Inc. now owns 5,717,966 shares of the biotechnology company’s stock worth $12,980,000 after purchasing an additional 776,715 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Agenus in the 1st quarter valued at $197,000. UBS Group AG raised its holdings in Agenus by 1,180.3% in the 1st quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock valued at $647,000 after acquiring an additional 126,684 shares during the last quarter. RTW Investments LP raised its holdings in Agenus by 0.7% in the 2nd quarter. RTW Investments LP now owns 9,375,451 shares of the biotechnology company’s stock valued at $21,282,000 after acquiring an additional 61,895 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its holdings in Agenus by 6.3% in the 1st quarter. Allianz Asset Management GmbH now owns 245,965 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 14,634 shares during the last quarter. Hedge funds and other institutional investors own 35.48% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Agenus (AGEN) Trading 6.3% Higher” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2018/11/15/agenus-agen-trading-6-3-higher.html.
About Agenus (NASDAQ:AGEN)
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Recommended Story: Why does a company issue an IPO?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.